{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:59:24Z","timestamp":1793444364589,"version":"4.5.0"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Bivalirudin (Angiomax; The Medicines Company, Parsippany, NJ), a direct thrombin inhibitor, has found increasing utilization as a heparin alternative in the pediatric population, most commonly for the treatment of thrombosis secondary to heparin-induced thrombocytopenia. Due to the relative rarity of heparin-induced thrombocytopenia as well as the lack of Food and Drug Administration\u2013approved indications in this age group, much of what is known regarding the pharmacokinetics and pharmacodynamics of bivalirudin in this population has been extrapolated from adult data. This narrative review will present recommendations regarding the use of bivalirudin for procedural anticoagulation in the pediatric population based on the published literature.<\/jats:p>","DOI":"10.1213\/ane.0000000000002835","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T23:35:38Z","timestamp":1518737738000},"page":"43-55","source":"Crossref","is-referenced-by-count":29,"title":["Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review"],"prefix":"10.1213","volume":"128","author":[{"given":"Katherine L.","family":"Zaleski","sequence":"first","affiliation":[{"name":"From the Department of Anesthesiology, Perioperative, and Pain Medicine, Boston Children\u2019s Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology, Perioperative, and Pain Medicine, Boston Children\u2019s Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane G.","family":"Nasr","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology, Perioperative, and Pain Medicine, Boston Children\u2019s Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230721","first-page":"e182","article-title":"Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.","volume":"14","author":"Moffett","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"R2-20230721","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics.","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R3-20230721","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1203\/01.PDR.0000156515.49293.F8","article-title":"Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.","volume":"57","author":"Baier","year":"2005","journal-title":"Pediatr Res"},{"key":"R5-20230721","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1538-7836.2007.02623.x","article-title":"Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis.","volume":"5","author":"Young","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R6-20230721","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/pbc.21731","article-title":"Bivalirudin for anticoagulation in children.","volume":"51","author":"Rayapudi","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20230721","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/jth.13057","article-title":"UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis.","volume":"13","author":"O\u2019Brien","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R8-20230721","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1051\/ject\/201143005","article-title":"Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literature.","volume":"43","author":"Pollak","year":"2011","journal-title":"J Extra Corpor Technol"},{"key":"R9-20230721","doi-asserted-by":"crossref","first-page":"R275","DOI":"10.1186\/cc10556","article-title":"Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation.","volume":"15","author":"Ranucci","year":"2011","journal-title":"Crit Care"},{"key":"R10-20230721","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/PCC.0b013e31827200b6","article-title":"Bivalirudin in pediatric patients maintained on extracorporeal life support.","volume":"14","author":"Nagle","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"R11-20230721","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.healun.2013.01.1056","article-title":"Antithrombotic strategies in children receiving long-term Berlin Heart EXCOR ventricular assist device therapy.","volume":"32","author":"Rutledge","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"R12-20230721","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2150135114553476","article-title":"Plasma exchange on venovenous extracorporeal membrane oxygenation with bivalirudin anticoagulation.","volume":"6","author":"Preston","year":"2015","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"R14-20230721","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ccd.20739","article-title":"Successful anticoagulation with bivalirudin in antithrombin-deficient pediatric patient undergoing stent placement.","volume":"68","author":"Zamora","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"R15-20230721","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s00246-008-9231-2","article-title":"Successful use of bivalirudin for superior vena cava recanalization and stent placement in a child with heparin-induced thrombocytopenia.","volume":"29","author":"Breinholt","year":"2008","journal-title":"Pediatr Cardiol"},{"key":"R16-20230721","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ccd.22817","article-title":"Pediatric catheterization laboratory anticoagulation with bivalirudin.","volume":"77","author":"Forbes","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"R17-20230721","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.healun.2006.08.005","article-title":"Successful use of bivalirudin for cardiac transplantation in a child with heparin-induced thrombocytopenia.","volume":"25","author":"Almond","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"R18-20230721","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1525-1594.2009.00961.x","article-title":"The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients.","volume":"34","author":"Gates","year":"2010","journal-title":"Artif Organs"},{"key":"R19-20230721","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/0267659111419037","article-title":"Novel techniques in the use of bivalirudin for cardiopulmonary bypass anticoagulation in a child with heparin-induced thrombocytopenia.","volume":"26","author":"Dragomer","year":"2011","journal-title":"Perfusion"},{"key":"R20-20230721","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1051\/ject\/201244069","article-title":"Alternative anticoagulation during cardiovascular procedures in pediatric patients with heparin-induced thrombocytopenia.","volume":"44","author":"Argueta-Morales","year":"2012","journal-title":"J Extra Corpor Technol"},{"key":"R21-20230721","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1051\/ject\/201648039","article-title":"Bivalirudin anticoagulation for a pediatric patient with heparin-induced thrombocytopenia and thrombosis requiring cardiopulmonary bypass for ventricular assist device placement.","volume":"48","author":"Faella","year":"2016","journal-title":"J Extra Corpor Technol"},{"key":"R22-20230721","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/IMCRJ.S118250","article-title":"Perioperative care in an adolescent patient with heparin-induced thrombocytopenia for placement of a cardiac assist device and heart transplantation: case report and literature review.","volume":"10","author":"Kamata","year":"2017","journal-title":"Int Med Case Rep J"},{"key":"R23-20230721","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/hc0802.104331","article-title":"Direct thrombin inhibitors in acute coronary syndromes: present and future.","volume":"105","author":"Weitz","year":"2002","journal-title":"Circulation"},{"key":"R24-20230721","first-page":"408","article-title":"Bivalirudin as an alternative to heparin for anticoagulation in infants and children.","volume":"20","author":"Buck","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R25-20230721","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0038-1651573","article-title":"Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.","volume":"69","author":"Fox","year":"1993","journal-title":"Thromb Haemost"},{"key":"R26-20230721","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1160\/TH05-03-0154","article-title":"Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.","volume":"94","author":"Warkentin","year":"2005","journal-title":"Thromb Haemost"},{"key":"R27-20230721","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.thromres.2004.02.012","article-title":"Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration.","volume":"113","author":"Casserly","year":"2004","journal-title":"Thromb Res"},{"key":"R28-20230721","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.amjcard.2004.05.068","article-title":"Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention.","volume":"94","author":"Cheneau","year":"2004","journal-title":"Am J Cardiol"},{"key":"R29-20230721","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction.","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"R30-20230721","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1051\/ject\/200537364","article-title":"Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery.","volume":"37","author":"Zucker","year":"2005","journal-title":"J Extra Corpor Technol"},{"key":"R31-20230721","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1213\/01.ane.0000205746.50440.98","article-title":"Measurement of patients\u2019 bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: a comparison to a standard activated clotting time.","volume":"102","author":"Carroll","year":"2006","journal-title":"Anesth Analg"},{"key":"R32-20230721","first-page":"383","article-title":"Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass.","volume":"96","author":"Koster","year":"2003","journal-title":"Anesth Analg"},{"key":"R33-20230721","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0036-1597297","article-title":"Laboratory monitoring of parenteral direct thrombin inhibitors.","volume":"43","author":"Van Cott","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"R34-20230721","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/01.CIR.87.5.1622","article-title":"Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty.","volume":"87","author":"Topol","year":"1993","journal-title":"Circulation"},{"key":"R35-20230721","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"R36-20230721","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.","volume":"142","author":"Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"R37-20230721","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","article-title":"Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).","volume":"143","author":"Lincoff","year":"2002","journal-title":"Am Heart J"},{"key":"R38-20230721","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjcard.2004.01.033","article-title":"Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).","volume":"93","author":"Lincoff","year":"2004","journal-title":"Am J Cardiol"},{"key":"R39-20230721","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"R40-20230721","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patient with acute coronary syndromes.","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"R41-20230721","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"R42-20230721","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"R43-20230721","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI.","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"R44-20230721","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"R45-20230721","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jcin.2014.10.015","article-title":"Novel Approaches for Preventing or Limiting Events (NAPLES) III trial.","volume":"8","author":"Briguori","year":"2015","journal-title":"J Am Coll Cardiol Intv"},{"key":"R46-20230721","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehu182","article-title":"Prasugrel plus bivalirudin vs clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.","volume":"35","author":"Schulz","year":"2014","journal-title":"Eur Heart J"},{"key":"R47-20230721","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"R48-20230721","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes.","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"R49-20230721","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamacardio.2016.5975","article-title":"One-year mortality for bivalirudin vs heparins plus optional glycoprotein IIb\/IIIa inhibitor treatment started in the ambulance for ST-segment elevation myocardial infarction: a secondary analysis of the EUROMAX randomized clinical trial.","volume":"2","author":"Fabris","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R50-20230721","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction.","volume":"377","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"},{"key":"R51-20230721","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.amjcard.2014.04.033","article-title":"Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb\/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.","volume":"114","author":"Nairooz","year":"2014","journal-title":"Am J Cardiol"},{"key":"R52-20230721","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2015.10.006","article-title":"An updated meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.","volume":"171","author":"Shah","year":"2016","journal-title":"Am Heart J"},{"key":"R53-20230721","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"key":"R54-20230721","doi-asserted-by":"crossref","first-page":"e003515","DOI":"10.1161\/JAHA.116.003515","article-title":"Prolonged high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: novel insights from an updated meta-analysis.","volume":"5","author":"Fahrni","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R55-20230721","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4244\/EIJV10I3A54","article-title":"Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty.","volume":"10","author":"Kini","year":"2014","journal-title":"EuroIntervention"},{"key":"R56-20230721","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cjca.2015.02.029","article-title":"Bivalirudin vs heparin in patients who undergo transcatheter aortic valve implantation.","volume":"31","author":"Lange","year":"2015","journal-title":"Can J Cardiol"},{"key":"R57-20230721","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.jacc.2015.10.003","article-title":"Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: the randomized BRAVO-3 trial.","volume":"66","author":"Dangas","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R58-20230721","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.amjcard.2003.10.021","article-title":"Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting.","volume":"93","author":"Koster","year":"2004","journal-title":"Am J Cardiol"},{"key":"R59-20230721","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jtcvs.2004.09.016","article-title":"Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study.","volume":"129","author":"Koster","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R60-20230721","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtcvs.2005.09.057","article-title":"A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.","volume":"131","author":"Dyke","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R61-20230721","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","article-title":"Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.","volume":"83","author":"Koster","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R63-20230721","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MBC.0b013e328201c9a9","article-title":"Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.","volume":"18","author":"Young","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R64-20230721","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1213\/ANE.0000000000001947","article-title":"Recombinant factor VIIa is associated with increased thrombotic complications in pediatric cardiac surgery patients.","volume":"124","author":"Downey","year":"2017","journal-title":"Anesth Analg"},{"key":"R65-20230721","first-page":"108","article-title":"Bivalirudin use in an infant with persistent clotting on unfractionated heparin.","volume":"16","author":"Malloy","year":"2011","journal-title":"J Pediatr Pharmacol Ther"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000539-201901000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:28:11Z","timestamp":1786112891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-201901000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000002835","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}